Compare MBUU & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBUU | IPSC |
|---|---|---|
| Founded | 1982 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.4M | 441.9M |
| IPO Year | 2013 | 2021 |
| Metric | MBUU | IPSC |
|---|---|---|
| Price | $28.32 | $2.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $32.20 | $4.25 |
| AVG Volume (30 Days) | 302.1K | ★ 2.1M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.74 | 91.30 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $807,561,000.00 | $109,164,000.00 |
| Revenue This Year | $2.14 | N/A |
| Revenue Next Year | $12.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $23.84 | $0.44 |
| 52 Week High | $39.65 | $2.97 |
| Indicator | MBUU | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 57.17 | 50.26 |
| Support Level | $28.10 | $2.14 |
| Resistance Level | $29.79 | $2.53 |
| Average True Range (ATR) | 1.32 | 0.17 |
| MACD | 0.25 | -0.02 |
| Stochastic Oscillator | 77.47 | 44.68 |
Malibu Boats is a designer and manufacturer of power boats in the United States. It is a market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a producer of sterndrive boats, in 2017, and Pursuit Boats, which makes high-end offshore and outboard motorboats, in 2018. In 2021, it purchased Maverick Boat Group, a seller of flat fishing boats, with exposure to bay, dual console, and center console boats. Most recently, in 2026, it tied up with Saxdor Yachts, focused on adventure dayboats. Malibu has also expanded into boat trailers and accessories, and in 2020, began producing its own engines for its performance sport boats.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.